ETA Industry-sponsored Satellite Symposia

Saturday, 6th September

Santiago Room
16.00-18.00 ETA Industry-Sponsored Satellite Symposium 1

Personalizing Management of Hypothyroidism: One Size Does Not Fit All

Sunday, 7th September

Compostela Room
07.00 – 08.00 ETA Industry-Sponsored Satellite Symposium 2

The Future is Now: Optimizing Treatment for Your RAI-R DTC Patients

Santiago Room
13.00-14.00 ETA Industry-Sponsored Satellite Symposium 3

Transformed Care for Advanced Medullary Thyroid Cancer: Incorporating the Right Treatments for the Right Patient at the Right Time

Santiago Room
19.00-20.30 ETA Industry-Sponsored Satellite Symposium 4

A new treatment alternative for targeted therapy in medullary thyroid cancer
Monday, 8th September

Santiago Room
13.00-14.00 ETA INDUSTRY-Sponsored Satellite Symposium 5
Hypothyroidism: New Developments in Thyroid Substitution Therapy

Tuesday, 9th September

Santiago Room
13.00-14.00 ETA INDUSTRY-Sponsored Satellite Symposium 6
New Trends in the Management of Thyroid Cancer
# Programme Overview - Saturday, 6th September 2014

<table>
<thead>
<tr>
<th>Room</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 25</td>
<td>08.15-15.15</td>
<td><strong>Advanced Thyroid, Neck Ultrasonography &amp; Ultrasound-assisted Procedures</strong></td>
</tr>
<tr>
<td>Obradoiro Room</td>
<td>08.30-15.30</td>
<td><strong>ICCIDD West-Central Europe Regional Meeting</strong></td>
</tr>
</tbody>
</table>
| Compostela Room | 09.00-14.30| **Spanish Society Satellite Symposium**
|             |            | Avances en el Diagnóstico y Tratamiento de Enfermedad Tiroidea /
|             |            | Advances in the Diagnosis and Treatment of Thyroid Diseases             |
| Room 14    | 10.00-15.30| **Basic Thyroid Course**
|            |            | Hypothalamus-pituitary-thyroid axis in health and disease               |
| Santiago Room | 11.00-13.50| **ETA-CRN Meeting**
|             |            | Controversies in Thyroid Cancer Management                             |
| Santiago Room | 14.00-15.00| **TFI Patient Forum and AECAT**                                     |
**Santiago Room**
16.00-18.00  ETA Industry-Sponsored Satellite Symposium 1

**Personalizing Management of Hypothyroidism: One Size Does Not Fit All**

**Santiago Room**
18.00-18.15  Opening Ceremony

*Welcome by Furio Pacini and Clara Alvarez*

**Santiago Room**
18.15-19.00  The European Thyroid Journal Lecture

*Chairperson: Wilmar Wiersinga, The Netherlands*

*Editor-in-Chief of the European Thyroid Journal*
Compostela Room
07.00 – 08.00 ETA Industry-Sponsored Satellite Symposium 2
The Future is Now: Optimizing Treatment for Your RAI-R DTC Patients

Santiago Room
08.00-10.00 Oral Session 1: Topic Highlights (OP1-OP6)
Chairpersons: Furio Pacini, Italy and Clara Alvarez, Spain

08.00-08.20
OP01 A ZEBRAFISH MODEL OF NETRN1 DEFICIENCY REVEALS ABNORMAL THYROID MORPHOGENESIS LINKED TO DEFECTIVE CARDIOVASCULAR DEVELOPMENT
Robert Opitz1, Achim Trubiroha1, Isabelle Vandernoot1, Marc-Philip Hitz2, Rasha Abu-Khoudir2, Valérie Désilets2, Johnny Deladoey2, Gregor Andelfinger2, Sabine Costagliola1
1IRRhM, Université Libre de Bruxelles, Brussels, Belgium; 2Department of Pediatrics, Centre Hospitalier Universitaire Sainte Justine, Montréal, Québec, Canada

08.20-08.40
OP02 ANALYSES OF A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131I-REFRACTORY DIFFERENTIATED THYROID CANCER (SELECT)
Steven L. Sherman1, Makoto Tahara2, Lori Wirth3, Bruce Robinson4, Marcia F. Brose5, Rossella Elisei6, Corina E. Dutcus7, Begoña de las Heras8, Junming Zhu9, Mouhammed Amir Habra1, Kate Newbold9, Manisha H. Shah10, Ana O. Hoff11, Andrew G Gianoukakis12, Naomi Kiyota13, Matthew H. Taylor14, Sung-Bae Kim15, Monika K. Krzyzanowska16, Martin Schlumberger17
1Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; 2Department of Head and Neck Medical Oncology National Cancer Center Hospital East, Kashiwa, Japan; 3Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
4Kolling Institute of Medical Research, University of Sydney, New South Wales 2006, Australia; 5Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 6Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
7Eisai Inc, Woodcliff Lake, NJ, USA; 8Eisai Ltd, Hatfield, England, UK; 9The Royal Marsden Hospital National Health Service Trust, London, England, UK; 10Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Oh, USA; 11Instituto Do Cancer de Sao Paulo, Universidade de Sao Paulo, Sao Paulo, Brazil; 12Division of Endocrinology and Metabolism, Harbor-Ucla Medical Center, Torrance, Ca, USA; 13Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan; 14Knight Cancer Institute, Oregon Health and Science University, Portland, Or, USA; 15Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
16Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Uhn 619 University Avenue, Toronto, Ontario, Canada; 17Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris-Sud, Villejuif, France
08.40-09.00
OP03  TARGETED MUTATIONS IN MCT10 EXPAND THE SUBSTRATE SPECTRUM TO INCLUDE T4
Jörg Johannes1, Ulrich Schweizer1, Doreen Braun1, Kleinau Gunnar2
1Rheinische Friedrich-Wilhelms-Universität Bonn; Institut Für Biochemie und Molekularbiologie
2Charité - Universitätsmedizin Berlin; Institut Für Experimentelle Pädiatrische Endokrinologie

09.00-09.20
OP04  THE TARGETED INACTIVATION OF MEN1 GENE EXACERBATES RET/PTC3-INDUCED THYROID NEOPLASTIC TRANSFORMATION
Samia Selmi-Ruby1, Maria-Jésus Obregon2, Juliette Dupayrat3, Françoise Borson-Chazot3, Chang Zhang3
1Faculté de Médecine Rth-Laennec Crcl Umr 1052; 2Instituto de Investigations Biomedicas; 3Crcl-Umr1052

09.20-09.40
OP05  NEXT GENERATION SEQUENCING (NGS) REVEALS A HIGHLY FREQUENT MULTIGENIC INVOLVEMENT IN THE PATHOGENESIS OF CONGENITAL HYPOTHYROIDISM
Luca Persani1, Tiziana de Filippis2, Giulia Gelmini2, Federica Marelli2, Maria Cristina Vigone3, Mirella Moro2, Maria Carolina Salerno4, Giorgio Radetti5, Giovanna Weber6, Fabiana Guizzardi2
1University of Milan and Ircs Istituto Auxologico Italiano; 2Ircs Istituto Auxologico Italiano; 3San Raffele Hospital
4University of Naples; 5Hospital of Bolzano; 6San Raffaele Hospital and Vita-Salute University

09.40-10.00
OP06  SERUM MIRNAS AS A NON INVASIVE TOOL IN THE DIFFERENTIAL DIAGNOSIS OF THYROID NODULES IN A CAUCASIAN POPULATION
Tania Pilli1, Silvia Cantara1, Sebastiano Guidi2, Cevenini Gabriele3, Giulia Busonero4, Sandro Cardianale1, Francesco Dotta1, Furio Pacini1
1Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; 2Fondazione Umberto DI Mario Onlus, Toscana Life Sciences, Siena, Italy; 3Department of Medical Biotechnologies, University of Siena, Siena, Italy

10.00-10.30  COFFEE BREAK

Santiago Room
10.30-12.00  SYMPOSIUM 1: THYROID AND THE HEART
Chairpersons: George J. Kahaly, Germany and Ignacio Bernabeu-Moron, Spain

10.30-11.00  Cardiovascular complications: toxic nodules vs autoimmune thyroid disease
Bernadette Biondi, Italy

11.00-11.30  Cardiovascular mortality and long-term outcomes in thyroid disease
Thomas Brix, Denmark

11.30-12.00  Thyroid hormone resistance and cardiovascular disease
Carla Moran, United Kingdom
**Compostela Room**

**10.30-12.00 Symposium 2: Thyroid Hormone and Energy Expenditure**  
*Chairpersons: Eric Fliers, The Netherlands and Maria Jesus Obregon, Spain*

- **10.30-11.00** Mitochondrial actions of thyroid hormone  
  *Gerald Cabello, France*
- **11.00-11.30** Central roles of thyroid hormone signaling in brown fat thermogenesis  
  *Miguel Lopez, Spain*
- **11.30-12.00** Thyroid hormone and thermoregulation  
  *Jens Mittag, Sweden*

**Poster Area**

**12.00-13.00 Lunch and Poster Discussion PO1 (Posters P1-P121)**

**Poster Session 1: Graves’ Orbitopathy**  
*Chairperson: Alessandro Antonelli, Italy*

**Poster Session 2: Cardiovascular Effects**  
*Chairperson: Warner Simonides, The Netherlands*

**Poster Session 3: Thyroid and Environment 1**  
*Chairperson: Endre Nagy, Hungary*

**Poster Session 4: Thyroid in Reproduction and Development 1**  
*Chairperson: Bijay Vaidya, United Kingdom*

**Poster Session 5: Thyroid Function and Development**  
*Chairperson: Luca Persani, Italy*

**Poster Session 6: Hypothyroidism**  
*Chairperson: Joao de Castro, Portugal*

**Poster Session 7: Thyroid Cancer Diagnostics 1**  
*Chairperson: Roussanka Kovatcheva, Bulgaria*

**Poster Session 8: Thyroid Cancer Therapeutics 1**  
*Chairperson: Sophie Leboulleux, France*

**Poster Session 9: Medullary Thyroid Cancer**  
*Chairperson: Valeriano Leite, Portugal*

**Poster Session 10: Goiter and Nodules 1**  
*Chairperson: Murat Erdogan, Turkey*

---

**Santiago Room**

**13.00-14.00 ETA Industry-Sponsored Satellite Symposium 3**

*Transformed Care for Advanced Medullary Thyroid Cancer: Incorporating the Right Treatments for the Right Patient at the Right Time*
**14.00-14.45  MEET-THE-EXPERT 1-4**

**Room 14**
**14.00-14.45  MTE 1**
Current State of Rituximab therapy in thyroid disease  
Mario Salvi, Italy and Laszlo Hegedüs, Denmark

**Compostela Room**
**14.00-14.45  MTE 2**
Genetics and thyroid - from bench to bedside  
Tomasz Bednarczuk, Poland

**Santiago Room**
**14.00-14.45  MTE 3**
Microcarcinoma: treatment and follow up  
Laura Fugazzola, Italy

**Room 25**
**14.00-14.45  MTE 4**
Congenital hypothyroidism  
Nadia Schoenmakers, United Kingdom

**14.45-15.15  COFFEE BREAK**

**Santiago Room**
**15.15-15.30  ETA LISSITZKY PRIZE AWARD**

**Santiago Room**
**15.30-17.30  ORAL SESSION 2: YOUNG INVESTIGATORS SESSION/CLINICAL (OP07-OP14)**
Chairpersons: Peter Laurberg, Denmark and Jacques Orgiazzi, France

**15.30-15.45  OP07  TELOMERASE PROMOTER MUTATIONS, EXPRESSION AND LOCALIZATION IN DIFFERENTIATED THYROID CANCER**
Marina Muzza¹, Carla Colombo¹, Stefania Rossi², Valentina Cirello¹, Michela Perrino¹, Simone De Leo¹, Elisa Pignatti³, Manuela Simoni³, Gaetano Bulfamante², Laura Fugazzola¹
¹Department of Clinical Sciences and Community Health, University of Milan; Endocrine Unit, Fondazione Ircss Ca’ Granda, Milan; ²Department Health Sciences, University of Milan; Division of Pathology, San Paolo Hospital, Milan ³Unit and Chair of Endocrinology and Metabolism, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia; Department of Medicine, Endocrinology, Metabolism and Geriatrics, Azienda Usl of Modena

**15.45-16.00  OP08  DUAL GS-GQ VERSUS GQ SELECTIVE SIGNALLING DEFECTS IN CARBOXY-TERMINAL TSHR MUTANTS: IN VITRO AND CLINICAL CORRELATES**
16.00-16.15
OP09 IMAGE-GUIDED, TUMOR STROMA-TARGETED I-131 THERAPY OF HEPATOCELLULAR CARCINOMA (HCC) USING A HIF-1-SPECIFIC SODIUM IODIDE SYMPORTER GENE SYSTEM

Marta García1, Jacqueline van Sande2, Ainhoa Iglesias3, Helène Bony-Trifunovic3, Maria Cheuca4, Eric van den Akker5, Isolina Riaño6, Cristina Luzuriaga7, Patricia Crock8, Isabel González-Casado9, Jacques E. Dumont2, José C. Moreno1
5Pediatric Endocrinology. Sophia Children’s Hospital. Erasmus Medical Center. Rotterdam. The Netherlands.
9Pediatric Endocrinology. La Paz University Hospital. Madrid. Spain.

16.15-16.30
OP10 THE COACTIVATOR TAZ MODULATES THE PHENOTYPIC EXPRESSION OF NKX2.1 MUTANTS IN THE BRAIN-THYROID-LUNG SYNDROME.

Munich, Vilanova, de Tuthyref

16.30-16.45
OP11 EFFICACY AND TOXICITY OF VANDETANIB FOR ADVANCED MEDULLARY THYROID CANCER TREATMENT, THE FRENCH EXPERIENCE

Cecile Chougnet1, Martin Schlumberger2, Borget Isabelle3, TUTHYREF Network4
1Hospital Saint Louis
2Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris-Sud, Villejuif, France
3Gustave Roussy, Université Paris-Sud, Villejuif, France
4Tuthyref

16.45-17.00
OP12 METHYLATION PROFILING REVEALS MARKERS SPECIFIC TO DISTINCT RET MUTATIONS IN MEDULLARY THYROID CARCINOMA

Veronika Mancikova1, Esmeralda Castelblanco2, Agustín F. Fernández3, Lucia Inglada Pérez4, Aguirre De Cubas5, Salud Borrego6, Xavier Matias-Guiu7, Mario Encinas8, Mario F. Fraga9, Mercedes Robledo4
1Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (Cnio); 2Hospital Universitari Arnau de Vilanova, Lleida; 3Instituto Universitario de Oncología del Principado de Asturias, Oviedo; 4Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (Cnio); 5Iciiii Center for Biomedical Research on Rare Diseases (Ciberer)
4Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (Cnio), Madrid, Spain; 4Hospital Virgen del Rocio, Sevilla; 7Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, Irbleida
17.00-17.15
**OP13** SPONTANEOUS ABORTION AND STILLBIRTH ARE COMMON IN BOTH HYPERTHYROIDISM AND HYPOTHYROIDISM: A DANISH POPULATION-BASED STUDY OF 1,028,045 PREGNANCIES
Stine Linding Andersen¹, Jørn Olsen², Chun Sen Wu³, Peter Laurberg¹
¹Aalborg University Hospital; ²Aarhus University, Denmark

17.15-17.30
**OP14** INCREASED FAT MASS RESULTS IN HIGHER FREE T3 LEVELS IN CHILDREN
Pete N Taylor¹, Nicholas Timpson², Jonathan Tobias³, Colin Dayan¹
¹Institute of Molecular & Experimental Medicine; School of Medicine; Cardiff University; ²University of Bristol, UK

Compostela Room
15.30-17.30 ORAL SESSION 3: MTC AND ANAPLASTIC CARCINOMA (OP15-OP22)
**Chairpersons: Barbara Jarzab, Poland and Mercedes Robledo, Spain**

15.30-15.45
**OP15** ARE DIFFERENCES IN GENE EXPRESSION PROFILE BETWEEN TYPE OF RET MUTATION IN MEDULLARY THYROID CANCER PRESENT?
Małgorzata Oczko-Wojciechowska¹, Michał Swierniak², Małgorzata Kowalska¹, Tomasz Tyszkiewicz³, Agnieszka Pawłaczek³, Michał Jarzab⁴, Dagmara Rusinek⁴, Jadwiga Zebracka-Gala¹, Agnieszka Ćzarnecka⁵, Jolanta Krajewska⁶, Barbara Jarzab¹
¹Msc Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology; ²Msc Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology; ³Genomic Medicine; Department of General Transplant and Liver Surgery; Medical University of Warsaw; ⁴Msc Memorial Cancer Center and Institute of Oncology, Gliwice Branch, III Radiotherapy Clinic; ⁵Msc Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland; ⁶Department of Nuclear Medicine and Endocrine Oncology, Centre of Oncology M.Sklodowska-Curie Memorial Institute Gliwice Branch; ²M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch

15.45-16.00
**OP16** MILD HYPERCALCITONINEMIA IN PATIENTS WITH BENIGN DISEASES OF THE THYROID AND CALCIUM HOMEOSTASIS
Juergen Kratzsch¹, Stefan Karger¹, Friedhelm Raue², Joachim Feldkamp³, Sandra Scheel³, Tanja Diana⁴, Nina Mattheis⁴, George J. Kahaly⁴
¹University Hospital, Leipzig; ²Praxis Prof. Raue & Colleagues, Heidelberg; ³Klinikum Bielefeld, Bielefeld; ⁴Johannes Gutenberg University Medical Center, Germany

16.00-16.15
**OP17** DIVERGENT ROLES OF FORKHEAD FAMILY TRANSCRIPTION FACTOR PARALOGS IN MEDULLARY THYROID CARCINOMA
Mikael Nilsson¹, Shawn Liang², Camilla Ingeson², Therese Carlsson², Jakob Dahlberg³, Svante Jansson³, Akif Demir⁴, Henrik Fagman⁴
¹Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ²Sahlgrenska Cancer Center, University of Gothenburg; ³Department of Surgery, Sahlgrenska University Hospital; ⁴Department of Pathology, Sahlgrenska University Hospital

16.15-16.30
**OP18** EXOME SEQUENCING REVEALS THAT SOS1 GENE MUTATIONS CAUSE A SYNDROME WITH PHENOTYPIC FEATURES OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B BUT NO ENDOCRINOPATHY
16.30-16.45
**OP19 EFFICACY AND SAFETY OF VANDETANIB IN AGGRESSIVE AND SYMPTOMATIC MEDULLARY THYROID CANCER (MTC) – POST-HOC ANALYSIS FROM THE ZETA TRIAL (NCT00410761)**
Michael Kreissl1, Ole Hauch2, Alan Webster2, Martin Schlumberger3
1Department of Nuclear Medicine, Central Hospital of Augsburg, Augsburg, Germany; 2Astrazeneca, Macclesfield, UK
3Institut Gustave Roussy, Villejuif, France

16.45-17.00
**OP20 CLINICAL IMPACT OF RET GENETIC SCREENING OF IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE**
Francesca Casella1, Alessia Tacito1, Raffaele Ciampi1, Eleonora Molinaro1, Laura Agate1, Valeria Bottici1, Antonio Matrone1, Agnese Biagini1, Rossella Elisei1, Cristina Romei1
1Section of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

17.00-17.15
**OP21 REFERENCE RANGE OF SERUM CALCITONIN IN CHILDREN**
Maria Grazia Castagna1, Laura Fugazzola2, Fabio Maino1, Danila Covelli3, Fausta Sestini1, Chiara Ferraris Fusarini1, Carlo Scapellato4, Francesco Macchini6, Gabriele Cevenini7, Furio Pacini6
1Section of Endocrinology, University of Siena, Siena, Italy; 2Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 3Endocrine Unit, Fondazione Policlinico Ircs, Milan, Italy; 4Section of Endocrinology and Diabetology, University of Milan, Milan, Italy; 5Laboratory of Clinical Pathalogy, University of Milan, Milan, Italy; 6Laboratory of Clinical Pathalogy, University of Siena, Siena, Italy; 7Section of Pediatrics, University of Milan, Milan, Italy; 7Section of Surgery Bioengineering, University of Siena, Siena, Italy

17.15-17.30
**OP22 MOLECULAR PROFILING OF SPORADIC MEDULLARY THYROID CARCINOMA PATIENTS BY NEXT GENERATION SEQUENCING**
Vera Tiedje1, Saskia Ting2, Thomas Herold3, Kurt Werner Schmid2, Dagmar Führer-Sakel4
1Department of Endocrinology and Metabolism; University of Duisburg-Essen; 2Institute of Pathology; University Hospital Essen
3Institute of Pathology; University Hospital Essen; German Cancer Consortium (Dktk) Heidelberg; 4Department of Endocrinology and Metabolism; University Hospital Essen, Germany

17.30-17.45  **Break**
Santiago Room
19.00-20.30  ETA INDUSTRY-SPONSORED SATELLITE SYMPOSIUM 4
A new treatment alternative for targeted therapy in medullary thyroid cancer
Scientific Programme/ Monday, 8th September

Santiago Room
08.00-09.30 SYMPOSIUM 3: EPIDEMIOLOGY OF SPORADIC AND FAMILIAL THYROID CANCER
Chairpersons: Maria Alevizaki, Greece and Cristina Álvarez Escola, Spain

08.00-08.30 Regional variation in thyroid cancer incidence in Belgium
Annick van den Bruel, Belgium
08.30-09.00 Time trend of thyroid cancer in Italy
Cristina Romei, Italy
09.00-09.30 Familial non-medullary thyroid cancer
Marco Capezzone, Italy

Compostela Room
08.00-09.30 SYMPOSIUM 4: GENE REGULATION BY THYROID HORMONE RECEPTORS
Chairpersons: Ana Aranda, Spain and Duncan Bassett, United Kingdom

08.00-08.30 Thyroid hormone and hypothalamic functions
Balázs Gereben, Hungary
08.30-09.00 NCOR and SMRT in thyroid hormone action
Anthony Hollenberg, USA
09.00-09.30 Non classical regulation of gene expression by thyroid hormone
Lars Moeller, Germany

09.30-10.00 COFFEE BREAK

10.00-12.00 ORAL SESSION 4: THYROID AUTOIMMUNITY (OP23-OP30)
Chairpersons: Stefano Mariotti, Italy; Monica Marazuela, Spain

10.00-10.15
OP23 FIRST INTERNATIONAL STANDARDISATION OF A TSH-RECEPTOR STIMULATING AUTOANTIBODY BIOASSAY
Tanja Diana¹, Markus Lehmann¹, Jasmin Franken¹, Michael Kanitz¹, George J. Kahaly¹
¹Johannes Gutenberg University Medical Center, Mainz, Germany
10.15-10.30
OP24 MECHANISM OF TSHR ACTIVATION BY TSH AND THYROID STIMULATING ANTIBODIES
Jane Sanders1, Ricardo Nunez Miguel1, Paul Sanders1, Stuart Young1, Jadwiga Furmaniak1, Bernard Rees Smith1
1Firs Laboratories, Rsr Ltd, UK

10.30-10.45
OP25 CHANGES OF SERUM TSH RECEPTOR ANTIBODIES (TRAB) LEVELS IN PATIENTS WITH GRAVES' DISEASE (GD) SUBMITTED TO RADIOIODINE THERAPY (RAI)
Irene Campi1, Guia Vannucchi1, Danila Covelli1, Silvia Tirelli2, Rodari Marcello3, Giovanna Pepe4, Arturo Chiti4, Mario Salv1
1Department of Clinical Sciences and Community Health, Fondazione Ircs Ca' Granda Ospedale Maggiore Policlinico; 2Laboratory Medicine Unit, Fondazione Ircs Ca' Granda Ospedale Maggiore Policlinico; 3Department of Nuclear Medicine, Humanitas Clinical and Research Center, Rozzano; 4Department of Nuclear Medicine, Humanitas Clinical and Research Center, Rozzano.

10.45-11.00
OP26 THYROID AUTOIMMUNITY IS PREVALENT IN PATIENTS WITH CELIAC DISEASE AND THEIR FIRST DEGREE RELATIVES – A PROSPECTIVE, CONTROLLED STUDY
Detlef Schuppan1, Martin Rosenthal1, Mareike Roth1, Jessica Willim1, Elisa Kolbe1, Tanja Diana1, George J. Kahaly1
1Johannes Gutenberg University Medical Center, Mainz, Germany

11.00-11.15
OP27 INCREASED REGULATORY B LYMPHOCYTES (BREG) IN PATIENTS WITH HASHIMOTO'S THYROIDITIS AND ASSOCIATED AUTOIMMUNE DISORDERS
Ilenia Gatto1, Maria Giulia Santaguida2, Giorgio Mangino1, Susanna Carlotta Del Duca2, Camilla Virili2, Lucilla Gargano3, Giovanna Romeo4, Marco Centanni4
1Dept of Medico-Surgical Sciences and Biotechnologies, “sapienza” University of Rome, Latina, Italy; 2Dept of Experimental Medicine “sapienza” University of Rome, Latina, Italy; 3Endocrinology Unit, Santa Maria Goretti Hospital, Ausl Latina, Latina, Italy; 4“Inspazio” University of Rome Dept of Medico-Surgical Sciences and Biotechnologies Latina

11.15-11.30
OP28 GRAVES' DISEASE IS ASSOCIATED WITH A DEFECTIVE EXPRESSION OF THE IMMUNE REGULATORY MOLECULE GALECTIN-9 IN ANTIGEN-PRESENTING DENDRITIC CELLS
Ana Maria Ramos Levi1, Miguel A Sampedro-Núñez1, Sandra Campos3, Susana Leskela1, Ana Serrano4, Ana Rodriguez-Muñoz1, Rebeca Martínez1, Hortensia de la Fuente1, Roberto Gonzalez-Amaro2, Monica Marazuela1
1Hospital Universitario Princesa. Instituto de Investigación Princesa; 2Universidad San Luis Potosi

11.30-11.45
OP29 FETAL CELL MICROCHIMERISM AND HLA-G STATUS IN A LARGE SERIES OF AUTOIMMUNE THYROID DISEASES
Valentina Cirello1, Roberta Rizzo3, Milena Crippa4, Irene Campi4, Carla Colombo4, Guia Vannucchi4, Antonia Maffini1, Stefano Ferrero5, Palma Finelli6, Laura Fugazzola2
1Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 2Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy; 3Laboratory of Medical Cytogenetics and Molecular Genetics, Istituto Auxologico Italiano, Milan, Italy; 4Endocrine Unit, Fondazione Policlinico Ircs, Milan, Italy
11.45-12.00
OP30 GLYCOSYLATION PATTERN ANALYSIS OF GLYCOPROTEIN HORMONES AND THEIR RECEPTORS
Ricardo Nunez Miguel, Jane Sanders, Paul Sanders, Stuart Young, Jadwiga Furmaniak, Bernard Rees Smith
1Firs Laboratories, Rsr Ltd, UK

Compostela Room
10.00-12.00 ORAL SESSION 5: TISSUE SPECIFIC ACTIONS OF THYROID HORMONE (OP31-OP38)
Chairpersons: Robin Peeters, The Netherlands and Juan Bernal, Spain

10.00-10.15
OP31 ANALYSIS OF TRANSCRIPTOMIC LANDSCAPE ENLIGHTENS THE IMPACT OF HYPOTHYROIDISM ON NEUROGENESIS.
Ghislaine Morvan Dubois, Gothié Jean David, Clerget-Froidevaux Marie-Stephanie, Duvernois-Berthet Evelyne, Remaud Sylvie, Demeneix Barbara
1Umr 7221 Cnrs Mnhn; 2Umr 7221cnrs Mnhn; 3Umr 7221 Mnhn Cnrs, France

10.15-10.30
OP32 NF-KB SIGNALING IN THE HYPOTHALAMUS IS ESSENTIAL FOR THE RESPONSE OF THE CENTRAL HPT AXIS TO ACUTE INFLAMMATION.
Emmely de Vries, Ronny Haenold, Sigrun Horn, Eric Fliers, Falk Weih, Heike Heuer, Anita Boelen
1Academic Medical Center; 2Leibniz Institute for Age Research - Fritz Lipmann Institute (Fli); 3Leibniz Institute for Age Research - Fritz Lipmann Institute (Fli), Jena; Leibniz Research Institute for Environmental Medicine, Dusseldorf

10.30-10.45
OP33 RE-EXPRESSION OF TYPE 1 IODOTHYRONINE DEIODINASE REDUCES PROLIFERATION IN RENAL CANCER CELLS
Piotr Poplawski, Agnieszka Piekiełko-Witkowska
1Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Poland

10.45-11.00
OP34 EFFECTS OF THYROID HORMONE DERIVATIVES ON IN VITRO CHONDROGENESIS
Janine Martitz, Peter Hofmann, Alexandra Deichsel, Petra Seemann, Lutz Schomburg
1Institute for Experimental Endocrinology; 2Charite Berlin, Germany

11.00-11.15
OP35 DIFFERENTIAL EFFECTS OF CHRONIC, INTRAHYPOTHALAMIC THYROID HORMONE ADMINISTRATION IN THE VENTROMEDIAL AND PARAVENTRICULAR NUCLEUS
Zhi Zhang, EWout Foppen, Peter Bisschop, Anita Boelen, Andries Kalsbeek, Eric Fliers
1Academic Medical Centre; 2Academic Medical Centre; Netherlands Institute for Neuroscience (Nin)
11.15-11.30
OP36 CARDIAC REGENERATION AND THYROID HORMONE: A STUDY IN METAMORPHOSING XENOPUS LAEVIS
Céline Vivien1, Lindsey Marshall1, Louise Péricard1, Fabrice Girardot1, Barbara Demeneix2, Laurent Coen1
1Unr Cnrs 7221, Département Régulations, Développement Et Diversité Moléculaire, Muséum National D’histoire Naturelle – Paris; 2Unr Cnrs 7221, Département Régulations, Développement Et Diversité Moléculaire, Muséum National D’histoire Naturelle

11.30-11.45
OP37 THYROID HORMONE T3 IS A MITOGENIC AND ANTIAP OPTOTIC FACTOR IN RAT GRANULOSA CELLS AND FOLLICLES
Cecilia Verga Falzacappa1, Virginia Di Paolo2, Claudia Mangialardo3, Alessandra Scamporrino1, Valentina Andriolo1, Ilenia Cammarata1, Silvia Misiti1, Rita Canipari2, Marco Centanni4
1Experimental Medicine Department,Sapienza, University of Rome; 2Department of Anatomy, Histology, Forensic Medicine and Orthopedic, Section of Histology, Sapienza; 3Dept of Medico-Surgical Sciences and Biotechnologies, “sapienza” University of Rome, Latina, Italy; 4“Sapienza” University of Rome Dept of Medico-Surgical Sciences and Biotechnologies Latina

11.45-12.00
OP38 A NEW GENE PREDISPOSING TO CONGENITAL HYPOTHYROIDISM
Angela Pascarella1, Giuseppe Ferrandino2, Maria Basile3, Olga Spadaro1, Fulvio D Angelo2, Chiara D’Ambrosio3, Andrea Scalonì3, Mario De Felice2, Roberto Di Lauro1, Gabriella De Vita1, Elena Amendola1
1Dipartimento DI Medicina Molecolare E Biotecnologie Mediche, Universita’ Federico II, Napoli, Italia; 2Istituto DI Ricerche Genetiche G.Salvatore, Biogem S.C.Ariano, Avellino, Italia; 3Proteomics & Mass Spectrometry Laboratory, Ispaam, National Research Council

Poster Area
12.00-13.00 LUNCH AND POSTER DISCUSSION PO2 (POSTERS P122-238)

Poster Session 13: Graves’ Orbitopathy and Autoimmunity
Chairperson: Marie-Christine Many, Belgium

Poster Session 14: Heart and Thyroid
Chairperson: Fabio Monzani, Italy

Poster Session 15: Subclinical Thyroid Disease and Hypothyroidism
Chairperson: Pete Taylor, United Kingdom

Poster Session 16: Thyroid and Environment 2
Chairperson: Massimo Tonacchera, Italy

Poster Session 17: Thyroid Cancer Diagnostics 2
Chairperson: Stéphane Bardet, France

Poster Session 18: Thyroid Cancer Pathogenesis 1
Chairperson: Thera Links, The Netherlands

Poster Session 19: Thyroid Cancer Therapeutics 2
Chairperson: Antonino Belfiore, Italy

Poster Session 20: Thyroid Hormone Availability and Action
Chairperson: Georg Brabant, Germany

Poster Session 21: Thyroid in Reproduction and Development 2
Chairperson: Kris Poppe, Belgium
Poster Session 22: Case Reports 2
Chairperson: Milos Sarkovic, Serbia

Poster Session 23: Goiter and Nodules 2
Chairperson: Laurence Du Pasquier-Fediaevsky, France

Santiago Room
13.00-14.00 ETA Industry-Sponsored Satellite Symposium 5
Hypothyroidism: New Developments in Thyroid Substitution Therapy

14.00-14.15 Coffee Break

14.15-15.00 Meet-the-Expert 5-8

Santiago Room
14.15-15.00 MTE 5
New insights into Graves’ disease
Michele Marino, Italy

Room 14
14.15-15.00 MTE 6
Structure & Function Relationship of TH transporters
Ulrich Schweizer, Germany

Compostella Room
14.15-15.00 MTE 7
Guidelines for management of subclinical hypothyroidism in pregnancy
John Lazarus, United Kingdom

Room 25
14.15-15.00 MTE 8
Vertebrate models for studying TH metabolism and action
Veerle Darras, Belgium

Santiago Room
15.00-17.00 Oral Session 6: Thyroid Cancer Diagnostics (OP39-OP46)
Chairpersons: Efisio Puxeddu Italy and Manuel Puig Domingo, Spain

15.00-15.15
OP39 IS AN INCREASE IN THYROID NODULE VOLUME A PREDICTOR OF MALIGNANCY?
Hirotoshi Nakamura¹, Mitsuyoshi Hirokawa¹, Minoru Kihara¹, Akihiro Miwa¹, Akira Miyauchi¹
¹Kuma Hospital, Japan

15.15-15.30
OP40 MOLECULAR TESTING OF ROUTINE AIR-DRIED FINE NEEDLE ASPIRATION (FNA) SMEARS IMPROVES PRE-SURGICAL DIAGNOSIS AND SUPPORTS THE HISTOLOGICAL IDENTIFICATION OF FOLLICULAR CARCINOMAS
Markus Eszlinger¹, Simonetta Piana², Anja Moll¹, Eileen Boesenberg¹, Ralf Paschke¹
¹Division of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany; ²Pathology Unit, Arcispedale Santa Maria Nuova-Irccs, Reggio Emilia, Italy
15.30-15.45
OP41 RE-EVALUATIONG THE MALIGNANCY RISK OF THYROID FOLLICULAR NEOPLASMS: A TWO-YEAR STUDY ON 598 CASES
Bénédicte Rover1, Claude Bigorgne2, Gilles Russ3, Agnès Rouxel2, Marie Bienvenu4
1Centre de Pathologie Et D'imagerie; 2Centre de Pathologie Et D'imagerie; La Pitié-Salpêtrière Hospital; 3Centre de Pathologie Et D'imagerie; La Pitié-Salpêtrière Hospital; 4Centre de Pathologie Et D'imagerie; Cochin Hospital

15.45-16.00
OP42 DIAGNOSTIC PERFORMANCE OF ELASTOGRAPHY IN CYTOLOGICALLY INDETERMINATE THYROID NODULES
Francesca Garino1, Maurilio Deandrea1, Federico Ragazzoni1, Alberto Mormile1, Nicola Palestini2, Milena Freddi2, Guido Gasparri2, Manuela Motta3, Donatella Pacchioni4, Paolo Piero Limone1
1Department of Endocrinology, Diabetes and Metabolism, AOU Mauriziano; 2Department of Surgery, Scu General Surgery III, AOU Città Della Salute E Della Scienza; 3Department of Diagnostic and Clinical Pathology, AOU Mauriziano; 4Department of Laboratory Medicine, Scu Diagnostic Anatomy and Histopathology, AOU Città Della Salute E Della Scienza

16.00-16.15
OP43 PREDICTIVE VALUE OF HIGH SENSITIVE THYROGLOBULIN ASSAY (USTG) AND NECK ULTRASONOGRAPHY (US) AT THE TIME OF REMNANT ABLATION ON LT-4 THERAPY IN PATIENTS WITH LOW AND INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER (DTC)
Antonio Matrone1, Carla Gambale1, Eleonora Molinaro1, Laura Agate1, Valeria Bottici1, Agnese Biagini1, David Viola1, Paolo Vitti1, Rossella Elisei1
1University of Pisa, Endocrine Unit - Department of Clinical and Experimental Medicine, Pisa, Italy

16.15-16.30
OP44 LOCALLY INVASIVE PAPILLARY THYROID CARCINOMA INVOLVING A FUNCTIONING RECURRENT LARYNGEAL NERVE EXCLUSIVELY MAY BE TREATED BY SHAVING TECHNIQUE WITH MACROSCOPIC RESIDUAL TUMOR FOLLOWED BY HIGH-DOSE RADIOIODINE THERAPY
Hyoung Shin Lee1, Kang Dae Lee1, Jun Woong Song2, Gi Yun Nam2, Sung Won Kim2, Seon Mi Baek3, Hyo Sang Park3
1Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine; 2Kosin University College of Medicine; 3Sharing and Happiness Hospital

16.30-16.45
OP45 MOLECULAR TESTING OF RESIDUAL THINPREP MATERIAL INCREASES SENSITIVITY AND ALLOWS MOLECULAR DIAGNOSTICS FOR CYTOLOGICALLY NON-DIAGNOSTIC SAMPLES
Jeffrey Krane1, Markus Eszlinger2, Edmund Cibas1, Ralf Paschke2
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 2Division of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany

16.45-17.00
OP46 PREDICTIVE VALUE OF ULTRASENSITIVE SERUM TG AT ABLATION IN DIFFERENTIATED THYROID CANCER PATIENTS
Silvia Memmo1, Maria Grazia Castagna1, Valentina Belardini1, Fabio Maino1, Carla Fioravanti1, Fausta Sestini1, Gabriele Cevenini2, Furio Pacini1
1Section of Endocrinology, University of Siena, Siena, Italy; 2Section of Surgery Bioengineering, University of Siena, Siena, Italy
Compostela Room
15.00-17.00 ORAL SESSION 7: THYROID HORMONE TRANSPORTERS AND DEIODINASES (OP47-OP54)
Chairpersons: Lutz Schomburg, Germany and Edward Visser, The Netherlands

15.00-15.15
OP47 STRONG INDUCTION OF DEIODINASES BY NOVEL SELENOCOMPOUNDS
Mette Stoedter1, Elena Ibanez2, Kostja Renko3, Janine Martitz1, Eddy Rijntjes4, Nicole Pietschmann3, Alfonso Calvo2, Juan A. Palop5, Sanmartin Grijalba Carmen2, Lutz Schomburg1
1Institute for Experimental Endocrinology
2Universidad de Navarra
3Charite Berlin
4Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany

15.15-15.30
OP48 THR92ALA D2-POLYMORPHISM DETERMINES REDUCED T4-INDUCED APOPTOSIS IN MUSCLE STEM CELLS
Monica Dentice1, Cristina Luongo1, Raffaele Ambrosio1, Tommaso Porcelli1, Daniela Di Girolamo1, Fausta Alfano1, Maria Angela De Stefano1, Domenico Salvatore1
1Department of Clinical Medicine and Surgery, University of Naples “Federico II, Italy

15.30-15.45
OP49 FIRST INSIGHTS INTO LAT2 AS T2 TRANSPORTER AND ITS STRUCTURE-FUNCTION RELATIONSHIPS
Anita Kinne1, Katrin Hinz2, Melanie Wittner2, Josef Köhrle3, Gerd Krause2
1Leibniz-Institut Für Molekulare Pharmakologie (Fmp), Berlin, Germany; 2Leibniz-Institut Für Molekulare Pharmakologie (Fmp)
3Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany

15.45-16.00
OP50 NOVEL THYROID HORMONE TRANSPORTERS: LAT3 AND LAT4 MEDIATE CELLULAR IODOTHYRONINE EFFLUX
Chantal Zevenbergen1, Edward Visser1, Robin Peeters1, Anita Kinne2, Gerd Krause2, Marcel Meima1, Theo Visser1
1Erasmus University Medical Center, Rotterdam, The Netherlands; 2Leibniz-Institut Für Molekulare Pharmakologie (Fmp), Germany

16.00-16.15
OP51 NEW INSIGHTS INTO THE MECHANISM OF DEIODINASE3
Ulrich Schweiger1, Doreen Braun, Christine Schlicker3, Josef Köhrle4, Clemens Steegborn5
1Rheinische Friedrich-Wilhelms-Universität Bonn; Institut Für Biochemie und Molekularbiologie; 2Rheinische Friedrich-Wilhelms-Universität Bonn; Institut Für Biochemie und Molekularbiologie; 3Ruhr-University Bochum; 4Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany; 5University of Bayreuth

16.15-16.30
OP52 FUNCTIONAL CHARACTERISTICS OF MCT8 ORTHOLOGS: INSIGHTS FROM HUMAN, MOUSE AND ZEBRAFISH
Simone Kersseboom6, Ramona E.A. van Heerebeek4, Francisco J. Arjona2, W. Edward Visser4, Robin P. Peeters3, Theo J. Visser1
1Erasmus University Medical Center; 2Radboud University Nijmegen, The Netherlands
16.30‐16.45
OP53 HYPOTHALAMIC THYROID HORMONE SENSING REGULATES TORPOR INDUCTION.
Eva K. Wirth¹, Monja Willershäuser², Franziska Meyer¹, Eddy Rijntjes³, Marc Klein⁴, Arnaud Agin⁵, Martin Hrabě de Angelis⁶, Josef Köhrle³, Martin Klingenspor², Jan Rozman⁷, Ulrich Schweizer⁸
¹Institut Für Experimentelle Endokrinologie, Charité Universitätsmedizin Berlin; ²Molecular Nutritional Medicine, Else‐Kröner Fresenius Center, Technische Universität München; ³Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany; ⁴Service D'endocrinologie, Centre Hospitalier Et Universitaire de Nancy; ⁵Icube Umr 7357, Université de Strasbourg/Cnr; ⁶German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München; Center of Life and Food Sciences Weihenstephan, Technische Universität München; German Center for Diabetes Research, Neuherberg
⁷Molecular Nutritional Medicine, Else‐Kröner Fresenius Center, Technische Universität München; German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München; German Center for Diabetes Research, Neuherberg
⁸Rheinische Friedrich‐Wilhelms‐Universität Bonn ; Institut Für Biochemie und Molekularbiologie

16.45‐17.00
OP54 THYROID HORMONE DEGRADING ENZYME TYPE 3 DEIODINASE (D3) IS PRESENT IN HUMAN NEUTROPHILS
Anne van der Spek¹, Monica Dentice², Domenico Salvatore³, Eric Fliers¹, Anita Boelen¹
¹Academic Medical Centre, The Netherlands; ²Department of Clinical Medicine and Surgery, University of Naples “federico II” ³Università DI Napoli “Federico II”, Italy
Scientific Programme/ Tuesday, 9th September

**Santiago Room**

08.00-09.30 Symposium 5: Thyroid Disease during pregnancy and childhood
*Chairpersons: Marek Niedziela, Poland and Jose Moreno, Spain*

08.00-08.30 Iodine deficiency in pregnancy and neurodevelopment  
*Margaret Rayman, United Kingdom*

08.30-09.00 Graves’ disease in children  
*Juliane Leger, France*

09.00-09.30 Thyroid disease during pregnancy and childhood  
*Françoise Borson-Chazot, France*

**Compostela Room**

08.00-09.30 Symposium 6: Pathological functions of MCT8  
*Chairpersons: Heike Heuer, Germany and Carlos Dieguez, Spain*

08.00-08.30 Role of MCT8 in the brain  
*Juan Bernal, Spain*

08.30-09.00 MCT8 and metabolism  
*Caterina di Cosmo, Italy*

09.00-09.30 Therapeutic options for MCT8 patients  
*Theo Visser, The Netherlands*

09.30-10.00 Coffee Break

**Santiago Room**

10.00-12.00 Oral Session 8: Hyperthyroidism and Orbitopathy (OP55-OP62)  
*Chairpersons: Luigi Bartalena, Italy and Fernando Cordido*

10.00-10.15  
**OP55** Diagnosis and Management of Graves’ Disease in Europe - Results of a Survey Among Members of the European Thyroid Association (ETA)  
*Luigi Bartalena¹, Henry B. Burch², George J. Kahaly³*
10.15-10.30
OP56  THYROID STIMULATING AUTOANTIBODIES ARE CLINICALLY USEFUL AND PREDICTIVE IN GRAVES’ DISEASE - A PROSPECTIVE TRIAL
George I. Kahaly1, Michael Kanitz1, Elisa Kolbe1, Nina Matheis1, Tanja Diana1
1Johannes Gutenberg University Medical Center, Mainz, Germany

10.30-10.45
OP57  EFFECTS OF TRIIODOTHYRONINE ON BONE MARROW AND SPLENIC GRANULOCYTES AND MONOCYTES POPULATIONS
Flavia Bloise1, Felipe Leite Oliveira2, Huila Fonseca2, Samuel dos Santos Valença2, Radovan Borojevic2, Carmen Cabanelas Pazos-Moura3, Valéria de Mello-Coelho2
1Institute of Biomedical Sciences; Institute of Biophysics Carlos Chagas Filho. Federal University of Rio de Janeiro; Academic Medical Central. University of Amsterdam; Capes; 2Institute of Biomedical Sciences; 3Institute of Biophysics Carlos Chagas Filho

10.45-11.00
OP58  THYROXINE-INDUCED CHANGES OF THE PLASMA PROTEOME – A STUDY OF EXPERIMENTAL HYPERTHYROIDISM IN HUMANS
Beatrice Engelmann1, Anna-Luise Dirk2, Elke Hammer3, Alexander Iwen4, Henri Wallaschofski4, Uwe Völker4, Georg Homuth3, Georg Brabant2
1Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald; 2Experimental and Clinical Endocrinology, University of Luebeck; 3Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald
4Interfaculty Institute for Genetics and Functional Genomics

11.00-11.15
OP59  DECREASE OF GLUT4 AND T3 AND INCREASE OF NOX2 ARE INVOLVED IN THE OXIDATIVE STRESS OF EYE MUSCULAR CELLS AND ORBITAL ADIPOCYTES IN GRAVES’ ORBITOPATHY
Van Regemorter Elliott1, Julie Craps2, Joris Virginie1, Behets Catherine1, Benoît Lengelé2, Baldeschi Lelio1, Chantal Daumerie3, Marie-Christine Many2
1Ucl; 2Université Catholique de Louvain, Morphologie Expérimentale; 3Cliniques Universitaires Saint-Luc; Université Catholique de Louvain

11.15-11.30
OP60  ROLE OF ALTERNATE TSHR LIGANDS AND BINDING PROTEINS (TSHR-BP) IN GRAVES’ ORBITOPATHY (GO)
Mohd Shazli Draman1, Fiona Grennan-Jones1, Lei Zhang1, Pete N Taylor1, Daniel Morris3, Carol Lane5, Colin Dayan1, Marian Ludgate1
1Institute of Molecular & Experimental Medicine; School of Medicine; Cardiff University
5Department of Ophthalmology; University Hospital of Wales

11.30-11.45
OP61  THE EFFECT OF RITUXIMAB (RTX) AND INTRAVENOUS MethylPREDNISOLONE (IVMP) ON TSH-RECEPTOR ANTIBODIES (TRAB) AND THE CXCL-10 CHEMOKINE IN PATIENTS WITH ACTIVE GRAVES’ ORBITOPATHY (GO)
Guia Vannucchi1, Irene Campi2, Danila Covelli2, P Fallahi3, S Tirelli4, A Di Domenicoantonio3, Nicola Curró5, Davide Dazzi6, Alessandro Antonelli3, Mario Salvi2
1Endocrine Unit, Fondazione Polyclinico Ircs, Milan, Italy; 2Endocrine Unit, Fondazione Ircs Ca’ Granda, Milan
3Department of Clinical and Experimental Medicine, University of Pisa; 4Laboratory Medicine Unit, Fondazione Ca’ Granda Ircs
11.45-12.00
OP62 FORKHEAD TRANSCRIPTION FACTORS; POSSIBLE TARGETS FOR THERAPY IN GO?
Lei Zhang1, Fiona Ruge2, Mohd Shazli Draman1, Fiona Grennan-Jones1, Carol Lane3, Colin Dayan4, Marian Ludgate1
1Institute of Molecular & Experimental Medicine; School of Medicine; Cardiff University; 2Cardiff-Peking Cancer Institute; School of Medicine; Cardiff University; 3Department of Ophthalmology; University Hospital of Wales

Compostela room
10.00-12.00 Oral Session 9: Thyroid Cancer Pathogenesis (OP63-OP70)
Chairpersons: Chris McCabe, United Kingdom and Pillar Santisteban, Spain

10.00-10.15
OP63 A NOVEL MODULATOR OF CELL INVASION AND METASTASIS
Rachel Watkins1, Vicki Smith1, Neil Sharma1, Martin Read1, Perkin Kwan1, Rachel Fletcher1, Vikki Poole1, Waraporn Imrueaicharaonchoke1, Kristien Boelaert1, Jayne Franklyn1, Christopher McCabe1
1University of Birmingham, United Kingdom

10.15-10.30
OP64 AN INTRONIC DELETION IN PHOSPHOLIPASE-C B1 (PLCB1) ASSOCIATED WITH EUTHYROID MULTINODULAR GOITRE (MNG) AND RISK OF PROGRESSING TO PAPILLARY THYROID CANCER (PTC)
Ioannis Ladas1, Fiona Grennan-Jones1, Ameen Bakhsh1, Lei Zhang1, Anna de Lloyd1, Denise Zwanziger2, Dagmar Fuhrer-Sakel2, Marian Ludgate1
1Cardiff University, Thyroid Research Group, Institute of Molecular and Experimental Medicine, Cardiff, United Kingdom
2Klinik Fur Endokrinologie, Universitatsklinikum, Essen, Germany

10.30-10.45
OP65 SELECTIVE KILLING AND SUBSEQUENT SENESCENCE INDUCTION: A DOUBLE ACTION FOR ANAPLASTIC THYROID CANCER THERAPY.
Elisa Stellaria Grassi1, Valeria Vezzoli3, Irene Negri3, Giovanni Vitale2, Luca Persani2
1Dept. of Clinical Sciences & Community Health, University of Milan; 2Dept. of Clinical Sciences & Community Health, University of Milan; Division of Endocrine and Metabolic Diseases & Lab. of Endocrine and Metabolic Research, Irccs Istituto Auxologico Italiano

10.45-11.00
OP66 THE FIRST REPORTED MUTATIONS IN THE PITUITARY TUMOR-TRANSFORMING GENE (PTTG) BINDING FACTOR (PBF)
Waraporn Imrueaicharaonchoke1, Martin Read1, Joel Smith1, Vicki Smith1, Bhavika Modasia1, Vikki Poole1, Rachel Watkins1, Jayne Franklyn1, Kristien Boelaert1, Christopher McCabe1
1University of Birmingham, United Kingdom

11.00-11.15
OP67 CLM29 AND CLM3, TWO TYROSINE KINASE INHIBITORS, HAVE ANTINEOPLASTIC ACTIVITY IN VITRO IN PRIMARY CULTURES FROM ANAPLASTIC THYROID CANCER, OBTAINED FROM FINE NEEDLE ASPIRATION.
Alda Corrado1, Poupa Fallahi1, Silvia Martina Ferrari1, Guido Bocci1, Concettina La Motta1, Gabriele Materazzi1, Andrea Di Domenicantonio1, Romano Danesi1, Federico Da Settimo1, Paolo Miccoli1, Alessandro Antonelli1
1University of Pisa, Italy

11.15-11.30
OP68 ESTROGEN AND PROGESTERON RECEPTORS EXPRESSION IN DIFFERENTIATED THYROID CANCER: A ROLE IN THE RISK STRATIFICATION OF THYROID TUMORS
Simone De Leo1, Michela Perrino1, Carla Colombo1, Stefania Rossi2, Delfina Tosi2, Leonardo Vicentini3, Gaetano Bifulamante2, Laura Fugazzola1, Guia Vannucchi1
1Endocrinology, Fondazione Ca' Granda IRCCS, University of Milan, Italy; 2Pathology Unit, Ospedale San Paolo, University of Milan; 3Endocrine Surgery Unit, Fondazione IRCCS Cà Granda, Milan

11.30-11.45
OP69 INSULIN RESISTANCE: ANOTHER RISK FACTOR THAT INCREASES THE RISK OF RECURRENT IN PATIENTS WITH THYROID CANCER?
Fabian Pitoia1, Erika Abelleira1, Fernanda Bueno1, Carolina Urciuoli1
1Hospital de Clínicas - University of Buenos Aires

11.45-12.00
OP70 GENETIC PREDISPOSITION TO PAPILLARY THYROID CANCER
Dorota Kula1, Daria Handkiewicz-Junak1, Michal Kalemba1, Zbigniew Puch1, Malgorzata Kowalska1, Monika Kowal1, Tomasz Tyszkwicz1, Renata Cyplinska1, Joanna Polanska2, Barbara Jarzab1
1Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; 2Silesian University of Technology, Poland

Poster Area
12.00-13.00 LUNCH AND POSTER DISCUSSION 3 (POSTERS 239-367)

Poster Session 24: Thyroid Autoimmunity
Chairperson: Marian Ludgate, United Kingdom

Poster Session 25: Hyperthyroidism
Chairperson: Patrice Rodien, France

Poster Session 26: Novel Actions of Thyroid Hormone
Chairperson: Heike Biebermann, Germany

Poster Session 27: Paediatrics and Pregnancy
Chairperson: Juliane Leger, France

Poster Session 28: Thyroid Cancer Diagnostics 3
Chairperson: Leonidas Duntas, Greece

Poster Session 29: Thyroid Cancer Diagnostics 4
Chairperson: Tania Pilli, Italy

Poster Session 30: Thyroid Cancer Pathogenesis 2
Chairperson: Kalliopi Paizaitou-Panayiotou, Greece

Poster Session 31: Thyroid Hormone and Gene Expression
Chairperson: Barbara Demeneix, France

Poster Session 32: Case Reports 3
Chairperson: Valentin Fadayev, Russia

Poster Session 33: Thyroid Cancer Therapeutics 3
Chairperson: Roland Gärtner, Germany
Poster Session 34: Thyroid Cancer Therapeutics 4  
Chairperson: Matthias Schott, Germany

Poster Session 35: Biochemical and Metabolic Parameters  
Chairperson: Tomasz Bednarczuk, Poland

Santiago Room
13.00-14.00 ETA INDUSTRY-SPONSORED SATELLITE SYMPOSIUM 6
New Trends in the Management of Thyroid Cancer

14.00-14.45 Meet-the-Expert 9-12

Santiago Room
14.00-14.45 MTE 9
Management of Follicular neoplasms  
Paolo Vitti, Italy

Compostela Room
14.00-14.45 MTE 10
Thyroid hormones and bones  
Graham Williams, United Kingdom

Room 14
14.00-14.45 MTE 11
Nuclear medicine imaging in thyroid disease  
Markus Luster, Germany

Room 25
14.00-14.45 MTE 12
Non-thyroidal illness  
Anita Boelen, The Netherlands

14.45-15.00 Coffee Break

Santiago Room
15.00-17.00 ORAL SESSION 10: CLINICAL THYROIDOLOGY (OP71-OP78)  
Chairpersons: Philippe Caron, France and Juan Carlos Galofré, Spain

15.00-15.15  
OP71 SUBCLINICAL HYPOTHYROIDISM AND THE RISK OF NON-FATAL AND FATAL STROKE: AN INDIVIDUAL PARTICIPANT ANALYSIS
Layal Chaker1, Christine Baumgartner2, Wendy J.P. den Elzen3, M. Arfan Ikram4, Manuel R. Blum5, Stephan J. L. Bakker5, Abbas Dehghan6, Christiane Drechsler7, Robert N. Luben8, Albert Hofman6, Marileen L.P. Portegies6, Marco Medici1, Giorgio Iervasi9, Tinh-Hai Collet2, Alexandra Brenner10, Christoph Wanner11, Massimo Iacoviello12, Robin P. Dullaart5, José A. Sgarbi13, Graziano Ceresini14, Rudi G. Westendorp15, J. Wouter Jukema 16, Misa Imaizumi17, Jayne A. Franklyn18, Douglas C.
OP72 MILD HYPERTHYROIDISM LEADS TO INCREASED CONNECTIVITY IN TEMPORAL LOBE STRUCTURES: A RESTING STATE FMRI STUDY

Anna-Luise Dirk1, Martin Göttlich2, Marcus Heldmann2, Anna Goebel2, Georg Brabant1, Thomas F. Muente2
1Experimental and Clinical Endocrinology, University of Luebeck; 2Department of Neurology, University of Luebeck, Germany

OP73 EUTHYROID AND HYPERTHYROID HAVE INCREASED RISK OF CEREBROVASCULAR EVENTS AFTER 131IODINE TREATMENT – A COHORT STUDY OF MORE THAN 5000 TREATED PATIENTS

Leppe Lerche la Cour1, Lars Thorbojorn Jensen2, Blrte Nygaard3
1Section of Clinical Physiology, Department of Diagnostics, Glostrup Hospital, University of Copenhagen; 2Section of Clinical Physiology, Department of Diagnostics, Glostrup Hospital, University of Copenhagen; 3Department of Endocrinology, Herlev Hospital

OP74 LOW SERUM THYROTROPIN LEVEL AND DURATION OF SUPPRESSION AS A PREDICTOR OF MAJOR OSTEOPOROTIC FRACTURES – THE OPENTHYRO REGISTER COHORT

Anne Sofie Laulund1, Bo Abrahamsen2, Henrik Løvendahl Jørgensen3, Mads Nybo4, Thomas Heiberg Brix1, Laszlo Hegedüs1
1Department of Endocrinology and Metabolism, Odense University Hospital; 2Research Centre for Aging and Osteoporosis, Odense University Hospital; 3Department of Clinical Biochemistry, Bispebjerg Hospital; 4Department of Clinical Biochemistry and Pharmacology, Odense University Hospital
16.00-16.15
OP75 RANDOMISED CONTROLLED PRE-CLINICAL TRIAL OF TRI-IODOthyronINE (T3) AND HYDROCORTISONE REPLACEMENT IN SEPTIC SHOCK.
Matthew Maiden1, Marianne Chapman1, Tim Kuchel2, David Torpy1, Iain Clarke3, Guy Ludbrook1
1Royal Adelaide Hospital; University of Adelaide; 2Sahmri; 3Monash University

16.15-16.30
OP76 BIRTH DEFECTS AFTER THE USE OF THE ANTITHYROID DRUGS (ATDS) METHIMAZOLE/CARBIMAZOLE (MMI/CMZ) AND PROPYLTHIOURACIL (PTU) IN PREGNANCY: HIGH RISK IS CONFINED TO A BRIEF TIME WINDOW OF PREGNANCY.
Peter Laurberg1, Stine Linding Andersen1
1Aalborg University Hospital

16.30-16.45
OP77 EVALUATION THE ASSOCIATION OF POLYMORPHISMS IN DIO1 AND DIO2 GENES WITH MENTAL, BIOCHEMICAL PARAMETERS AND QUALITY OF LIFE IN WOMEN WITH PRIMARY HYPOTHYROIDISM
Valentin Fadeyev1, Meruert Madiyarova4, Tatyana Morgunova1
1I.M. Sechenov First Moscow State Medical University, Department of Endocrinology, Russia

16.45-17.00
OP78 LONG-TERM SELENIUM SUPPLEMENTATION AND THYROTROPIN IN DANISH SENIORS. RESULTS FROM A RANDOMISED CONTROLLED TRIAL.
Kristian Winther1, Frederik Cold2, Steen Joop Bonnema1, Søren Cold2, Birgit Debrabant3, Mads Nybo4, Laszlo Hegedüs1
1Department of Endocrinology and Metabolism, Odense University Hospital, Denmark; 2Department of Oncology, Odense University Hospital, Denmark; 3Department of Epidemiology, Biostatistics and Biodemography, University of Southern Denmark, Odense, Denmark; 4Department of Clinical Biochemistry, Odense University Hospital, Denmark

Compostela Room
15.00-17.00 Oral Session 11: Young Investigators Session/Basic (OP79-OP86)
Chairpersons: Theo Visser, The Netherlands and Josef Köhrle, Germany

15.00-15.15
OP79 BIOSYNTHESIS OF 3-IODOthyronAMINE FROM THYROXINE IN INTESTINAL TISSUE
Carolin Höfig1, Tilo Wuensch2, Ina Lehmphul3, Hannelore Daniel4, Ulrich Schweizer5, Jens Mittag6, Josef Köhrle3
1Karolinska Institutet, Department of Cell & Molecular Biology, Sweden; 2Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany; 3Karolinska Institutet, Department of Cell & Molecular Biology, Sweden; Ziel Research Center of Nutrition and Food Science, Abteilung Biochemie, Technische Universität München, Germany
4Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany
5Ziel Research Center of Nutrition and Food Science, Abteilung Biochemie, Technische Universität München, Germany
6Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany
7Karolinska Institutet, Department of Cell & Molecular Biology, Sweden

15.15-15.30
OP80 REGULATION OF EMBRYONIC THYROID GROWTH BY MESENCHYMAL FGF10 COINCIDING WITH FUNCTIONAL DIFFERENTIATION
Shawn Liang1, Henrik Fagman2, Mikael Nilsson1
15.30-15.45
**OP81 IDENTIFICATION OF MIR-146B-3P AS A KEY PLAYER IN THYROID CANCER DEDIFFERENTIATION**
León Wert-Lamas¹, Garcilaso Riesco¹, Pilar Santisteban²
¹Iib Alberto Sols. Csic-Uam; ²Instituto de Investigaciones Biomédicas (Csic-Uam), Spain

15.45-16.00
**OP82 IN VIVO DISSECTION OF THE ROLE OF GLIS3 TRANSCRIPTION FACTOR IN THE HYPOTHALAMIC-PITUITARY-THYROID AXIS**
Federica Marelli¹, Franco Cotelli², Luca Persani³
¹Irccs Istituto Auxologico Italiano; ²University of Milan; ³Irccs Istituto Auxologico Italiano; University of Milan, Italy

16.00-16.15
**OP83 THE EFFECT OF DEIODINASE TYPE 3 KNOCKDOWN ON ZEBRAFISH EYE DEVELOPMENT.**
Anne M. Houbrechts¹, Enise Bagci², Marjolein Heijlen¹, Dries Knapen³, Veerle M. Darras¹
¹Laboratory of Comparative Endocrinology, Ku Leuven, Belgium; ²Systemic Physiological & Ecotoxicological Research, UA, Belgium; ³Veterinary Physiology and Biochemistry, UA, Belgium

16.15-16.30
**OP84 CHARACTERIZATION OF CHICKEN THYROID HORMONE TRANSPORTERS**
Nele Bourgeois¹, Stijn L.J. Van Herck¹, Joke Delbaere¹, Chantal Zevenbergen², Simone Kersseboom², Veerle M. Darras¹, Theo J. Visser²
¹Laboratory of Comparative Endocrinology, Ku Leuven, Belgium; ²Department of Internal Medicine, Erasmus University Medical Center, 3015 Ge Rotterdam, The Netherlands

16.30-16.45
**OP85 IMPACT OF THYROID HORMONES ON ERA-DEPENDENT ACTIONS IN THE HYPOTHALAMUS**
Larissa Faustino¹, Khatuna Gagnidze², Tania M Ortiga-Carvalho³, Donald Pfaff²
¹Universidade Federal Do Rio de Janeiro; The Rockefeller University; ²The Rockefeller University; ³Universidade Federal Do Rio de Janeiro

16.45-17.00
**OP86 ROLE OF THE NADPH OXIDASE NOX4 IN BRAFV600E-DEPENDENT DOWNREGULATION OF NIS.**
Azouzi Najma¹, Cailloux Jérémy¹, Boichard Amélie², Abir Al Ghuzlan³, Dana Hart³, Martin Schumberger⁴, Ameziane El Hassani Rabii⁵, Corinne Dupuy⁶
¹Université Paris-Sud 11; Umr 8200 Cars; Institut Gustave Roussy; ²Institut Gustave Roussy; ³Gustave Roussy, Université Paris-Sud, Villejuif, France; ⁴Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris-Sud, Villejuif, France; ⁵Ubrm, Centre National de l’énergie, des Sciences Et des Techniques Nucléaires, Rabat

---

**Santiago Room**

**17.00-17.45 ETA PRIZE LECTURE**
*Chairpersons: Furio Pacini, Italy and Colin Dayan, United Kingdom*

Iodine, thyroid autoimmunity and cancer
Santiago Room
18.00-19.15 General Assembly (for ETA members only)
Scientific Programme/ Wednesday, 10th September

Compostela Room
07.45-08.45  SHORT-CALL ABSTRACTS
Chairpersons: Furio Pacini, Italy; Colin Dayan, United Kingdom

Compostela Room
08.45-10.15 SYMPOSIUM 7: THYROID HORMONE REPLACEMENT
Chairpersons: Jean Louis Wemeau, France and Francesco Trimarchi, Italy

08.45-09.15 Risks of thyroid hormone replacement
Simon Pearce, United Kingdom
09.15-09.45 Trends in thyroid hormone prescribing, malabsorption and intolerance of thyroid hormone
Salvatore Benvenga, Italy
09.45-10.15 T3 vs T4 therapy
Colin Dayan, United Kingdom

Room 25
08.45-10.15 SYMPOSIUM 8: ADVANCED THYROID TUMORS:
STEPS BEFORE TARGET THERAPY
Chairpersons: Laurence Leenhardt, France and Javier Aller Pardo, Spain

08.45-09.15 Outcome of metastatic thyroid cancer
Cosimo Durante, Italy
09.15-09.45 The future of imaging evaluation of target lesions
TBD
09.45-10.15 Evaluation of the ratio benefits/QoL under TKI treatment
Kate Newbold, United Kingdom

10.15-10.30 COFFEE BREAK
Compostela Room
10.30-12.30 ORAL SESSION 12: THYROID CANCER THERAPY (OP87-OP94)
Chairpersons: Rossella Elisei, Italy and GarciaLo Riesco-Eizaguirre, Spain

10.30-10.45
**OP87** EXPLORATORY ANALYSIS OF OUTCOMES FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-RDTC) RECEIVING OPEN-LABEL SORAFENIB POST-PROGRESSION ON THE PHASE III DECISION TRIAL
Martin Schlumberger1, Christopher Nutting2, Barbara Jarzab3, Rossella Elisei4, Salvatore Siena5, Lars Bastholt6, Christelle de la Fouchardiere7, Furio Pacini8, Ralf Paschke9, Young Kee Shong10, Steven I Sherman11, Johannes WA Smit12, John Chung13, Christian Kappeler14, Istvan Molnar13, Marcia S Brose13
1Gustave Roussy; 2Royal Marsden Hospital; 3Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology
4Department of Clinical and Experimental Medicine, University of Pisa; 5Ospedale Niguarda Ca’ Granda; 6Odense University Hospital; 7Consortium Cancer Thyroiden, Hospices Civils-Centre Anticancéreux; 8Unit of Endocrinology, University of Siena
9Department for Endocrinology and Nephrology, Leipzig University; 10Asan Medicine Center, University of Ulsan College of Medicine; 11The University of Texas MD Anderson Cancer Center; 12Department of Internal Medicine, Radboud University Medical Center; 13Bayer Healthcare Pharmaceuticals; 14Bayer Pharma AG; 15Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Center of the University of Pennsylvania

10.45-11.00
**OP88** FOLLICULAR (FVPTC) VS CLASSICAL (CVPTC) VARIANT OF PAPILLAR THYROID CANCER: CORRELATION OF THE OUTCOME AFTER 12 YEARS OF FOLLOW UP
Carlotta Giani1, Liborio Torregrossa2, Eleonora Molinaro3, Andrea Cacciato Insilla4, Laura Agate1, David Viola1, Luciana Puleo1, Gabriele Materazzi2, Ivo Marchetti3, Paolo Miccoli2, Giancarlo Di Coscio3, Paolo Vitti1, Fulvio Basolo2, Rossella Elisei1
1Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
2Department of Surgical, Medical and Molecular Pathology of the Clinical Area, University of Pisa, Pisa, Italy
3Department of Translational Research and New Technologies in Medicine and Surgeons, University of Pisa, Pisa, Italy

11.00-11.15
**OP89** CONSERVATIVE VS RADICAL SURGICAL MANAGEMENT IN CHILDREN WITH DIFFERENTIATED THYROID CANCER: MULTICENTRIC STUDY
Claudio Spinelli1, Paolo Miccoli1, Alessandro Inserra2, Gianni Bisogno3, Giovanni Cecchetto3, Poupak Fallahi1, Alessandro Antonelli6
1University of Pisa; 2“bambino Gesù” Pediatric Hospital; 3University of Padova, Italy

11.15-11.30
**OP90** PROGNOSTIC VALUE OF MICROSCOPIC LYMPH NODE INVOLVEMENT IN PATIENTS WITH PAPILLARY THYROID CANCER
Stephane Bardet1, Renaud Giappucchini1, Elske Quak1, Jean-Pierre Rame1, David Blanchard1, Dominique De Raucourt1, Emmanuel Babin2, Jean-Jacques Michels1, Dominique Vaur1, Natacha Heutte3
1Centre Francois Baclesse; 2Chu; 3Université de Basse-Normandie, France

11.30-11.45
**OP91** METASTATIC THYROID CANCER UNRESPONSIVE TO CONVENTIONAL THERAPY TREATED WITH SORAFENIB “OFF-LABEL”: AN UPDATE OF OUR 6 YEARS OF EXPERIENCE
11.45-12.00
OP92 DIFFERENTIAL GENE EXPRESSION IN FOLLICULAR THYROID CARCINOMAS SHOWING DIFFERENT DEGREES OF INVASIVENESS
Ricardo Celestino1, Torfinn Nome2, Ana Pestana3, Eva Sigstad4, Ragnhild A. Lothe5, Trine Bjørø6, Manuel Sobrinho-Simões7, Rolf I. Skotheim2, Paula Soares8
1Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; School of Allied Health Sciences Estsp, Polytechnic of Porto, Porto, Portugal; 2Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 3Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Institute of Biomedical Sciences of University of Porto, Porto, Portugal; 4Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 5Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 6Department of Molecular Biosciences, University of Oslo, Oslo, Norway; 7Department of Medical Biochemistry, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 8Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Medical Faculty, University of Porto, Porto, Portugal; Department of Pathology, Centro Hospitalar de São João, Porto, Portugal
8Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal; Medical Faculty, University of Porto, Porto, Portugal

12.00-12.15
OP93 SURGICAL STRATEGY IN LOW ADVANCED DIFFERENTIATED HORMONE CANCER STAGED T1N0M0 - RESULTS OF A PILOT FEASIBILITY STUDY
Agnieszka Czarniecka1, Stanislaw Poltorak1, Aleksander Sacher1, Adam Maciejewski1, Jolanta Krajewska1, Michal Jarzab1, Ewa Stobiecka1, Ewa Zembala-Nozynska1, Ewa Chmielik1, Dagmara Rusinek1, Monika Kowal1, Małgorzata Oczko-Wojciechowska1, Daria Handkiewicz-Junak1, Barbara Jarzab1
1Centre of Oncology M.Skłodowska-Curie Memorial Institute Gliwice Branch, Poland

12.15-12.30
OP94 PERCUTANEOUS TREATMENT OF BONE METASTASES FROM DIFFERENTIATED THYROID CARCINOMAS: RESULTS FROM A COHORT OF 23 PATIENTS
Françoise Bonichon9, Cazzato Roberto Luigi1, Buy Xavier2, Godbert Yann3, Henriques de Figueiredo Bénédicte4, Pointillart Vincent5, Palussiere Jean6
1Dept of Diagnostic Imaging and Interventional Radiology Università Campus Bio-Medico Di Roma Via Alvaro del Portillo, 200 Rome; 2Department of Interventional Radiology, Institut Bergonié, 229 Cours de L’argonne, 33076, Bordeaux Cedex, France; 3Department of Nuclear Medicine, Institut Bergonié, 229 Cours de L’argonne, 33076, Bordeaux Cedex, France
4Department of Radiotherapy, Institut Bergonié, 229 Cours de L’argonne, 33076, Bordeaux Cedex, France
5Spinal Surgery Unit, Department of Orthopaedics, University Hospital of Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France; 6Department of Interventional Radiology, Institut Bergonié, 229 Cours de L’argonne, 33076, Bordeaux Cedex, France,
10.30-10.45
**OP95** THE TRANSCRIPTION FACTOR NRF2 CONTROLS ANTIOXIDANT RESPONSES AND IMPACTS THYROID-SPECIFIC GENE EXPRESSION AND HANDLING OF EXCESS IODINE
Panos Ziros, Ioannis Habeos, Dionysios Chartoumpekis, Michail Mpakakis, Irene Mamali, Stavroula Manolakou, Ioannis Lillis, Nikolaos Papachristou, Venetsana Kyriazopoulou, Thomas Kensler, Dionysios Papachristou, Gerasimos Sykiotis
1Lausanne University Hospital
2University of Patras Medical School
3University of Pittsburgh

10.45-11.00
**OP96** THE NUCLEAR COREPRESSOR NCOR IS AN ESSENTIAL MEDIATOR OF THE ANTI-TUMORIGENIC AND ANTI-METASTATIC ACTIONS OF THE THYROID HORMONE RECEPTOR β
Olaia Martinez-Iglesias, Rosa Martin-Orozco, Elvira Alonso-Merino, Juan Pedro Velasco-Martín, Javier Regadera, Jose Palacios, Pilar González-Peramato, Ana Aranda
1Instituto de Investigaciones Biomédicas; 2Universidad Autónoma de Madrid; 3Hospital Ramón Y Cajal; 4Hospital La Paz

11.00-11.15
**OP97** BEHAVIORAL AND METABOLIC EFFECTS OF 3-IODOTHYROACETIC ACID: ROLE OF HISTAMINE
Maria Elena Manni, Alessandro Saba, Annunziatina Laurino, Riccardo Donzelli, Grazia Chiellini, Riccardo Zucchi, Laura Raimondi
1University of Florence; 2University of Pisa, Italy

11.15-11.30
**OP98** IDENTIFICATION OF AN INTRA-MOLECULAR DISULFIDE BRIDGE ESSENTIAL FOR THE COVALENT AND FUNCTIONAL INTERACTION BETWEEN DUOX2 AND ITS PARTNER DUOXA2
Carré Aurore, Louzada Ruy, Ameziane El Hassani Rabii, Corinne Dupuy
1Université Paris-Sud 11; Umr 8200 Cnrs; Institut Gustave Roussy
2Laboratório de Fisiologia Endócrina Doris Rosenthal; Universidade Federal Do Rio de Janeiro
3Ubrm, Centre National de L'énergie, des Sciences Et des Techniques Nucléaires, Rabat

11.30-11.45
**OP99** THYROID HORMONES REDUCE THE TGFβ-DEPENDENT ACTIONS, ALLEVIATING FIBROTIC RESPONSES
Elvira Alonso-Merino, Rosa Martin-Orozco, Lidia Ruíz Llorente, Luis Fernanda Fanjul Rodríguez, Olaia Martinez-Iglesias, Juan Pedro Velasco-Martín, Javier Regadera, Ana Aranda
1Instituto de Investigaciones Biomédicas
2Universidad Autónoma de Madrid

11.45-12.00
**OP100** THYROMIMETIC ACTION OF 3,5-T2 IN DIET-INDUCED OBESE MICE
Julika Lietzow, Wenke Jonas, Priyavathi Dhandapani, Josef Köhrle
1Institut Für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, Germany
2German Institute of Human Nutrition (Dife), Nuthetal, Germany

12.00-12.15
**OP101** SELENIUM INCREASES THYROTROPHIN-INDUCED NIS EXPRESSION THROUGH APE1-DEPENDENT REGULATION OF PAX8 BINDING ACTIVITY
Suzana Leoni¹, Ana Sastre-Perona², Pilar Santisteban¹, Antonio De la Vieja³
¹Instituto de Investigaciones Biomédicas (Csic-Uam); ²Instituto de Investigaciones Biomédicas (Csic-Uam) - Madrid
³Instituto de Salud Carlos III (Área de Biología Celular Y Desarrollo, Centro Nacional de Microbiología), Spain

12.15-12.30
OP102 3-IODOTHYROACETIC ACID INDUCES GENERALIZED ITCH AND HYPERSENSITIVITY TO NOXIOUS HEAT STIMULI IN MOUSE
Annunziatina Laurino¹, Francesco Resta¹, Riccardo Zacchi², Laura Raimondi¹
¹University of Florence; ²University of Pisa, Italy

Compostela Room
12.30-13.00 YOUNG INVESTIGATOR AWARDS, POSTER PRIZES, JACK ROBBINS PRIZE AND CLOSING CEREMONY
President, Furio Pacini, Italy & Secretary, Colin Dayan, United Kingdom